email article
Treatment with cabozantinib (Cabometyx) significantly improved progression-free survival (PFS) in patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer, an interim analysis of a phase III study found.
In the intent-to-treat population of COSMIC-311, median PFS was not reached with cabozantinib, as compared to 1.9 months with placebo (HR 0.22, 96% CI 0.13-0.36, P